GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Cash Ratio

BOLD (Boundless Bio) Cash Ratio : 20.02 (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Boundless Bio's Cash Ratio for the quarter that ended in Jun. 2024 was 20.02.

Boundless Bio has a Cash Ratio of 20.02. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Boundless Bio's Cash Ratio or its related term are showing as below:

BOLD' s Cash Ratio Range Over the Past 10 Years
Min: 8.63   Med: 12.9   Max: 20.02
Current: 20.02

During the past 3 years, Boundless Bio's highest Cash Ratio was 20.02. The lowest was 8.63. And the median was 12.90.

BOLD's Cash Ratio is ranked better than
93.15% of 1475 companies
in the Biotechnology industry
Industry Median: 2.82 vs BOLD: 20.02

Boundless Bio Cash Ratio Historical Data

The historical data trend for Boundless Bio's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boundless Bio Cash Ratio Chart

Boundless Bio Annual Data
Trend Dec21 Dec22 Dec23
Cash Ratio
18.89 8.63 12.90

Boundless Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.69 12.78 12.90 9.85 20.02

Competitive Comparison of Boundless Bio's Cash Ratio

For the Biotechnology subindustry, Boundless Bio's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Boundless Bio's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Boundless Bio's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Boundless Bio's Cash Ratio falls into.


Boundless Bio Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Boundless Bio's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=120.752/9.359
=12.90

Boundless Bio's Cash Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash Ratio (Q: Jun. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=179.29/8.957
=20.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boundless Bio  (NAS:BOLD) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.

Boundless Bio Cash Ratio Related Terms

Thank you for viewing the detailed overview of Boundless Bio's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Boundless Bio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Cash Ratio
Comparable Companies
Traded in Other Exchanges
N/A
Address
9880 Campus Point Drive, Suite 120, San Diego, CA, USA, 92121
Website
https://www.boundlessbio.com
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.